secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001193125-25-241546
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon appoints Tucker Kelly as CFO; grants 225K options, 30K RSUs
-----------------------------------------------------------------

- Tucker Kelly named CFO effective Oct 15, 2025; previously CFO at Deciphera (acquired by Ono for $2.4B).
- Annual base salary $540K; eligible for incentive up to 45% of base.
- One-time inducement grant: options for 225K shares at $41.90 (closing price Oct 15).
- One-time grant of 30,000 RSUs; both options and RSUs vest over 4 years.
- Interim CFO Ian Mortimer steps down but remains President & CEO as lead candidate azetukalner enters Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312525241546/0001193125-25-241546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312525241546/xene-20251015.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer